Phase 1 clinical trial of PHB-050.
Latest Information Update: 12 Mar 2026
At a glance
- Drugs PHB 050 (Primary)
- Indications Atopic dermatitis; Food hypersensitivity
- Focus Adverse reactions
- Sponsors Poplar Therapeutics
Most Recent Events
- 03 Mar 2026 According to Poplar Therapeutics, the additional capital from the financing will support the continued advancement of the trial.
- 13 Jan 2026 New trial record
- 07 Jan 2026 According to Poplar Therapeutics, important data on safety, pharmacokinetics data from this trial expected the second half of 2026.